Skip to main content

Advertisement

Table 2 Patient characteristics (n = 28)

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

Characteristics Nb (%)
Sex
 Male (%) 18 (64)
 Female (%) 10 (36)
Age (median, range), years 63 (42–79)
Tobacco use (%) 23 (82)
Histologya
 Adenocarcinoma (%) 21 (75)
 Squamous cell carcinoma (%) 4 (14)
 Large cell carcinoma (%) 1 (4)
 Large cell neuroendocrine carcinoma (%) 1 (4)
 Lymphoepithelioma-like carcinoma (%) 1 (4)
Previous lines of chemotherapy (median, range) 2 (1–5)
Previous thoracic surgery 5 (18)
No. of nivolumab cycles (median, range) 11 (4–27)
  1. aAccording to the 2015 World Health Organization Classification of Lung Tumors [26]